Market overview
The global birch allergy treatment market is worth USD 307 mn in 2026 and is forecast to reach USD 551 mn by 2036, growing at a 6.0% CAGR. Germany is the largest country market and Subcutaneous injection extracts is the largest by product segment.
| Scope | Allergen immunotherapy for birch pollen allergy: subcutaneous injection extracts, sublingual tablets and sublingual drops, sold mainly in Northern and Central Europe and North America. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 290 mn |
| Value 2026 | USD 307 mn |
| Value 2036 | USD 551 mn |
| CAGR 2026-2036 | 6.0% |
| Volume 2026 | 357 thousand treatment courses |
| Volume 2036 | 579 thousand treatment courses |
| Average price 2026 | USD 862 per treatment course |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Birch Allergy Treatment market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 307 mn |
| 2027 | USD 326 mn |
| 2028 | USD 345 mn |
| 2029 | USD 366 mn |
| 2030 | USD 388 mn |
| 2031 | USD 411 mn |
| 2032 | USD 436 mn |
| 2033 | USD 462 mn |
| 2034 | USD 490 mn |
| 2035 | USD 519 mn |
| 2036 | USD 551 mn |
Birch Allergy Treatment market segmentation
By product
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Subcutaneous injection extracts | 48.0% | 35.9% | USD 148 mn | 3.0% |
| Sublingual tablets | 30.0% | 43.2% | USD 92 mn | 9.9% |
| Sublingual drops | 22.0% | 20.9% | USD 68 mn | 5.5% |
By patient age
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Adults | 62.0% | 59.2% | USD 191 mn | 5.5% |
| Adolescents | 20.0% | 21.0% | USD 61 mn | 6.5% |
| Children | 18.0% | 19.8% | USD 55 mn | 7.0% |
By treatment type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Allergen immunotherapy | 46.0% | 48.0% | USD 141 mn | 6.5% |
| Antihistamines | 24.0% | 22.0% | USD 74 mn | 5.1% |
| Nasal corticosteroids | 18.0% | 17.0% | USD 55 mn | 5.4% |
| Other therapies | 12.0% | 13.0% | USD 37 mn | 6.8% |
By administration route
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral and sublingual | 38.0% | 42.0% | USD 117 mn | 7.1% |
| Nasal | 26.0% | 24.0% | USD 80 mn | 5.2% |
| Subcutaneous injection | 22.0% | 22.0% | USD 68 mn | 6.0% |
| Ocular and topical | 14.0% | 12.0% | USD 43 mn | 4.4% |
By sales channel
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Retail pharmacies | 46.0% | 44.0% | USD 141 mn | 5.5% |
| Hospital pharmacies | 14.0% | 13.0% | USD 43 mn | 5.2% |
| Allergy clinics | 22.0% | 21.0% | USD 68 mn | 5.5% |
| Online pharmacies | 18.0% | 22.0% | USD 55 mn | 8.2% |
Top 25 countries for birch allergy treatment by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 74.0% of 2026 revenue and the 25 countries below together hold 93.5%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | Germany | USD 68 mn | 22.0% | USD 116 mn | 5.6% |
| 2 | France | USD 31 mn | 10.0% | USD 53 mn | 5.6% |
| 3 | United States | USD 25 mn | 8.0% | USD 46 mn | 6.5% |
| 4 | Netherlands | USD 18 mn | 6.0% | USD 33 mn | 6.0% |
| 5 | United Kingdom | USD 18 mn | 6.0% | USD 33 mn | 6.0% |
| 6 | Sweden | USD 15 mn | 5.0% | USD 28 mn | 6.0% |
| 7 | Italy | USD 15 mn | 5.0% | USD 25 mn | 5.1% |
| 8 | Denmark | USD 12 mn | 4.0% | USD 21 mn | 5.5% |
| 9 | Austria | USD 12 mn | 4.0% | USD 21 mn | 5.5% |
| 10 | Switzerland | USD 12 mn | 4.0% | USD 22 mn | 6.0% |
| 11 | Poland | USD 10.0 mn | 3.2% | USD 21 mn | 7.6% |
| 12 | Canada | USD 8.3 mn | 2.7% | USD 15 mn | 6.3% |
| 13 | Belgium | USD 6.9 mn | 2.2% | USD 13 mn | 6.4% |
| 14 | Finland | USD 6.7 mn | 2.2% | USD 12 mn | 6.3% |
| 15 | Norway | USD 5.2 mn | 1.7% | USD 9.5 mn | 6.3% |
| 16 | Spain | USD 3.9 mn | 1.3% | USD 7.3 mn | 6.4% |
| 17 | Czech Republic | USD 3.8 mn | 1.2% | USD 7.1 mn | 6.3% |
| 18 | Russia | USD 3.4 mn | 1.1% | USD 7.2 mn | 7.6% |
| 19 | Japan | USD 2.9 mn | 0.9% | USD 5.3 mn | 6.3% |
| 20 | Australia | USD 2.4 mn | 0.8% | USD 4.4 mn | 6.4% |
| 21 | Ireland | USD 1.7 mn | 0.6% | USD 3.1 mn | 6.4% |
| 22 | Hungary | USD 1.5 mn | 0.5% | USD 2.8 mn | 6.4% |
| 23 | Brazil | USD 1.4 mn | 0.4% | USD 2.8 mn | 7.6% |
| 24 | Slovakia | USD 1.1 mn | 0.4% | USD 2.1 mn | 6.3% |
| 25 | South Korea | USD 0.92 mn | 0.3% | USD 1.9 mn | 7.7% |
| Rest of world | USD 20 mn | 6.5% | USD 38 mn | 6.6% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- ALK-Abello
- Stallergenes Greer
Group 2: Regional and specialist players
- HAL Allergy
- Allergopharma
- Inmunotek
- Jubilant HollisterStier
- Bencard Allergie
- Diater
- Lofarma
Group 3: Emerging and niche players
- LETI Pharma
- Roxall
- Allergy Therapeutics
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the birch allergy treatment market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 6.0% is calculated from the resulting values.
The market is divided by product, by patient age, by treatment type, by administration route, by sales channel. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the birch allergy treatment market?
The global birch allergy treatment market is estimated at USD 290 mn in 2025 and USD 307 mn in 2026.
How fast will the birch allergy treatment market grow?
It is forecast to reach USD 551 mn by 2036, a compound annual growth rate of 6.0% from 2026, an increase of USD 243 mn.
Which country is the largest market for birch allergy treatment?
Germany is the largest market by revenue at USD 68 mn in 2026, 22.0% of the global total. The three largest countries together hold 40.0%.
Which country is growing fastest?
Among the ten largest markets, United States is growing fastest at 6.5% a year from 2026 to 2036.
Which birch allergy treatment segment is largest?
In the by product split, Subcutaneous injection extracts is the largest segment with 48.0% of 2026 revenue.
Who are the leading birch allergy treatment companies?
Global leaders include ALK-Abello, Stallergenes Greer.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Bladder Cancer ArrayUSD 308 mn · 9.0% CAGR
- Ophthalmic Stereoscopic 3D DisplayUSD 314 mn · 11.0% CAGR
- Alzheimer's Blood TestUSD 299 mn · 24.0% CAGR
- Bone Morphogenetic ProteinUSD 316 mn · 5.0% CAGR
- Kidney Transplant Rejection BiomarkerUSD 319 mn · 9.0% CAGR
- Veterinary Allergy DiagnosticsUSD 321 mn · 6.5% CAGR
- Digital StethoscopeUSD 286 mn · 10.0% CAGR
- Dental Implantology SoftwareUSD 283 mn · 8.5% CAGR